Gapping up
In reaction to earnings/guidance:
- PI +22.9%, GE +11%, SANM +10.4%, CURO +10.3%, GDI +7.5%, WWD +7.4%, MEDP +6.4%, NXPI +6.2%, YUMC +5.6%, AMRC +5%, BRX +4.8%, APRN +4.8%, AKS +4.5%, VRNS +4.2%, THC +3.4%, MLM +3.3%, CLR +3.1%, CMI +3%, MOH +2.7%, AUDC +2.5%, FDC +2.4%, SBAC +2.3%, MUSA +2.2%, BP +2.2%, TNET +2%, ECA +2%, RIG +1.9%, LDOS +1.7%, CCEP +1.6%, COP +1.4%, APTS +1.3%, MRK +1.3%, CHTR +1.1%, ARCC +1%, PFE +1%
Other news:
- SYBX +31.1% (presents data demonstrating its development of a robust and reproducible process to generate a solid oral formulation of its Synthetic Biotic medicine, SYNB1618)
- GTHX +16.4% (provided a regulatory update on trilaciclib)
- WAGE +13.9% (confirms that it has received an unsolicited, non-binding proposal from HealthEquity (HQY))
- APTX +7.9% (reports 'positive' results from Phase 1 study of NYX-458 in clinical development for the treatment of cognitive impairment associated with Parkinson's disease) NPTN +5.4% (initiated with Buy at MKM Partners)
- ARNC +1.4% (ahead of earnings tomorrow before the open)
- BDX +1.4% (receives FDA approval for BD ChloraPrep skin preparation with sterile solution)
- PNNT +1.3% (ticking higher; initiated with Outperform at Raymond James)
Analyst comments:
- OI +1.3% (upgraded to Buy from Hold at SunTrust)
- ON +1.3% (upgraded to Buy from Hold at Jefferies)